Chung W, Wang W, Challagundla L, Moore C, Egan S, Xu K
Oncogenesis. 2025; 14(1):2.
PMID: 39890784
PMC: 11785972.
DOI: 10.1038/s41389-025-00545-6.
Van Keymeulen A
Adv Exp Med Biol. 2025; 1464():167-184.
PMID: 39821026
DOI: 10.1007/978-3-031-70875-6_10.
Sanders E, Sun H, Tabatabaee S, Lang C, van Dijk S, Su Y
bioRxiv. 2025; .
PMID: 39803552
PMC: 11722240.
DOI: 10.1101/2024.12.29.630675.
Raiten J, Abd G, Handelsman S, Patel H, Ku J, Parsons A
Front Pharmacol. 2024; 15:1471563.
PMID: 39555101
PMC: 11564730.
DOI: 10.3389/fphar.2024.1471563.
Munshi S, Alarbi A, Zheng H, Kuplicki R, Burrows K, Figueroa-Hall L
Mol Psychiatry. 2024; 30(2):574-586.
PMID: 39174649
DOI: 10.1038/s41380-024-02695-2.
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.
Le Saux O, Ardin M, Berthet J, Barrin S, Bourhis M, Cinier J
Nat Commun. 2024; 15(1):5932.
PMID: 39013886
PMC: 11252308.
DOI: 10.1038/s41467-024-47000-5.
Tumor suppressor FRMD3 controls mammary epithelial cell fate determination via notch signaling pathway.
Ma J, Gong Y, Sun X, Liu C, Li X, Sun Y
Sci Adv. 2024; 10(27):eadk8958.
PMID: 38959315
PMC: 11221522.
DOI: 10.1126/sciadv.adk8958.
Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
Liu Y, Li M, Fang Z, Gao S, Cheng W, Duan Y
Cancer Immunol Immunother. 2024; 73(7):117.
PMID: 38713229
PMC: 11076447.
DOI: 10.1007/s00262-024-03699-1.
The Mayo Clinic Salivary Tissue-Organoid Biobanking: A Resource for Salivary Regeneration Research.
Aalam S, Varela A, Khaderi A, Mondesir R, Mun D, Ding A
bioRxiv. 2024; .
PMID: 38464033
PMC: 10925098.
DOI: 10.1101/2024.02.23.581761.
Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma.
Liu M, Bertolazzi G, Sridhar S, Lee R, Jaynes P, Mulder K
Nat Commun. 2024; 15(1):2113.
PMID: 38459052
PMC: 10923916.
DOI: 10.1038/s41467-024-46220-z.
Fatty acid amide hydrolase drives adult mammary gland development by promoting luminal cell differentiation.
Tundidor I, Seijo-Vila M, Blasco-Benito S, Rubert-Hernandez M, Moreno-Bueno G, Bindila L
Cell Death Discov. 2024; 10(1):12.
PMID: 38184644
PMC: 10771414.
DOI: 10.1038/s41420-023-01788-1.
A gene network-driven approach to infer novel pathogenicity-associated genes: application to PAO1.
De R, Whiteley M, Azad R
mSystems. 2023; 8(6):e0047323.
PMID: 37921470
PMC: 10734507.
DOI: 10.1128/msystems.00473-23.
Natural phenolic compounds as biofilm inhibitors of multidrug-resistant - the role of similar biological processes despite structural diversity.
Buchmann D, Schwabe M, Weiss R, Kuss A, Schaufler K, Schluter R
Front Microbiol. 2023; 14:1232039.
PMID: 37731930
PMC: 10507321.
DOI: 10.3389/fmicb.2023.1232039.
miR-203 drives breast cancer cell differentiation.
Martinez-Illescas N, Leal S, Gonzalez P, Grana-Castro O, Munoz-Oliveira J, Cortes-Pena A
Breast Cancer Res. 2023; 25(1):91.
PMID: 37542268
PMC: 10401798.
DOI: 10.1186/s13058-023-01690-9.
Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution.
Liu J, Ji Y, Weng X, Shao W, Zhao J, Chen H
Front Oncol. 2023; 13:1150098.
PMID: 37427097
PMC: 10328385.
DOI: 10.3389/fonc.2023.1150098.
Mellitin peptide quantification in seasonally collected crude bee venom and its anticancer effects on myelogenous K562 human leukaemia cell line.
Obeidat M, Al-Khraisat I, Jaradat D, Ghanim B, Abdallah Q, Arqoub D
BMC Complement Med Ther. 2023; 23(1):132.
PMID: 37098530
PMC: 10127481.
DOI: 10.1186/s12906-023-03897-x.
TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer.
Khatpe A, Dirks R, Bhat-Nakshatri P, Mang H, Batic K, Swiezy S
Cancer Res. 2023; 83(8):1345-1360.
PMID: 37057595
PMC: 10107402.
DOI: 10.1158/0008-5472.CAN-22-3667.
Clinicopathologic Correlation of CD44 + /CD24 - Expression in Breast Cancer: a Report from Tertiary Care Medical University in India.
Anand A, Gaurav K, Miller J, Singh K, Agrawal M, Kumar S
Indian J Surg Oncol. 2023; 14(1):204-207.
PMID: 36891450
PMC: 9986142.
DOI: 10.1007/s13193-022-01649-w.
Exploring the Value of Additional Primary Tumour Excision Combined with Systemic Therapy Administered in Different Sequences for Patients with de Novo Metastatic Breast Cancer.
Zhu S
Breast J. 2022; 2022:5049445.
PMID: 36082023
PMC: 9436631.
DOI: 10.1155/2022/5049445.
Fate decisions of breast cancer stem cells in cancer progression.
Xu H, Zhang F, Gao X, Zhou Q, Zhu L
Front Oncol. 2022; 12:968306.
PMID: 36046046
PMC: 9420991.
DOI: 10.3389/fonc.2022.968306.